Effect of surgical treatment on prognosis in patients with gastric signet<b>-</b>ring cell carcinoma: a SEER<b>-</b>based study_CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY

Authors：

CHEN Xinming , HUANG Kun ,  ZHAO Pingwu , HE Yunsheng , ZHAO Pan , LIU Yang

Department of General Surgery, Affiliated Mianyang Hospital of Chengdu University of Traditional Chinese Medicine, Mianyang, Sichuan 621000, P. R. China;

Corresponding author：

ZHAO Pingwu, Email: zhaopingwu01@hotmail.com

Keywords：

gastric signet-ring cell carcinoma; surgical treatment; prognosis; SEER database

DOI：

10.7507/1007-9424.202307058

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Objective To investigate the impact of surgical treatment on the prognosis of patients with gastric signet-ring cell carcinoma (GSRC). Methods The clinicopathologic and prognosis data of patients pathologically diagnosed with GSRC from 2000 to 2019 were extracted from the Surveillance, Epidemiology, and End Results (SEER) database. The Cox proportional hazards regression model was used to analyze the impact of surgery on overall survival (OS) and cancer-specific survival (CSS) of patients with GSRC. Results A total of 3 457 patients with GSRC were included, including 2 048 cases in the operation group and 1 409 cases in the non-operation group. The propensity-score matching by a 1∶1 nearest neighbour algorithm was conducted to control for confounding baseline differences. There were 802 cases in the operation group and 802 cases in the non-operation group after matching. The OS and CSS curves drawn by Kaplan-Meier method of the operation group were better than those of the non-operation group (χ²=434.3 P<0.001; χ²=412.4, P<0.001). The multivariate Cox proportional hazards regression analysis showed that the elderly (≥ 60 years old), late AJCC tumor stage (stage Ⅰ as reference), and patients with bone metastasis of GSRC increased the risk of shortening OS and CSS (P<0.05), while patients treated with surgery and chemotherapy decreased the risk of shortening OS and CSS (P<0.05). Conclusion According to the analysis results of SEER database in this study, surgical treatment is beneficial to improve the prognosis for patients with GSRC.

Citation： CHEN Xinming, HUANG Kun, ZHAO Pingwu, HE Yunsheng, ZHAO Pan, LIU Yang. Effect of surgical treatment on prognosis in patients with gastric signet-ring cell carcinoma: a SEER-based study. CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY, 2023, 30(12): 1472-1477. doi: 10.7507/1007-9424.202307058 Copy

1.	Japanese Gastric Cancer Association. Japanese gastric cancer treatment guidelines 2014 (ver. 4). Gastric Cancer, 2017, 20(1): 1-19.
2.	沈亦敏, 李元元, 王舟, 等. 不同病理亚型胃印戒细胞癌的临床预后分析. 解放军医学杂志, 2023-10-27. http://kns.cnki.net/kcms/detail/11.1056.R.20230526.1736.008.html.
3.	Pernot S, Voron T, Perkins G, et al. Signet-ring cell carcinoma of the stomach: impact on prognosis and specific therapeutic challenge. World J Gastroenterol, 2015, 21(40): 11428-11438.
4.	Taghavi S, Jayarajan SN, Davey A, et al. Prognostic significance of signet ring gastric cancer. J Clin Oncol, 2012, 30(28): 3493-3498.
5.	Bamboat ZM, Tang LH, Vinuela E, et al. Stage-stratified prognosis of signet ring cell histology in patients undergoing curative resection for gastric adenocarcinoma. Ann Surg Oncol, 2014, 21(5): 1678-1685.
6.	张莉芊, 陈闽霞, 杨沛轩, 等. 术后辅助放疗对中晚期胃印戒细胞癌患者预后的影响: 基于人群的回顾性研究. 第二军医大学学报, 2021, 42(9): 981-987.
7.	黄坤, 赵平武, 白斗, 等. 不同病理学类型的腹膜后脂肪肉瘤患者的预后分析及临床评价. 中国普通外科杂志, 2021, 30(10): 1212-1228.
8.	Chen XB, Xu ZJ, Liu T, et al. Analysis of related risk factors and prognostic factors of gastric cancer with bone metastasis: a SEER-based study. J Immunol Res, 2022, 2022: 3251051. doi: 10.1155/2022/3251051.
9.	Wang J, Qin D, Tao Z, et al. Identification of cuproptosis-related subtypes, construction of a prognosis model, and tumor microenvironment landscape in gastric cancer. Front Immunol, 2022, 13: 1056932. doi: 10.3389/fimmu.2022.1056932.
10.	Joshi SS, Badgwell BD. Current treatment and recent progress in gastric cancer. CA Cancer J Clin, 2021, 71(3): 264-279.
11.	Yu JI, Lim DH, Lee J, et al. Necessity of adjuvant concurrent chemo-radiotherapy in D2-resected LN-positive gastric cancer. Radiother Oncol, 2018, 129(2): 306-312.
12.	Deb S, Austin PC, Tu JV, et al. A review of propensity-score methods and their use in cardiovascular research. Can J Cardiol, 2016, 32(2): 259-265.
13.	Benedetto U, Head SJ, Angelini GD, et al. Statistical primer: propensity score matching and its alternatives. Eur J Cardiothorac Surg, 2018, 53(6): 1112-1117.
14.	Liu L, Wang Q, Yuan H. Clinicopathological characteristics and prognostic factors of primary bladder signet ring cell carcinoma. J Healthc Eng, 2022, 2022: 3224616. doi: 10.1155/2022/3224616.
15.	Fung BM, Patel M, Patel N, et al. Signet ring cell gastric carcinoma: clinical epidemiology and outcomes in a predominantly Latino county hospital population. Dig Dis Sci, 2021, 66(4): 1240-1248.
16.	Yu JM, Zhan ZW, Zhen JX, et al. Clinical characteristics and prognostic analysis of patients with signet ring cell gastric carcinoma. Technol Cancer Res Treat, 2020, 19: 1533033820983812. doi: 10.3389/fsurg.2022.819018.
17.	Biondi A, D’Ugo D, Cananzi F, et al. Prognostic indicators in stage Ⅳ surgically treated gastric cancer patients: a retrospective multi-institutional study. Dig Surg, 2019, 36(4): 331-339.
18.	Cheng Y, Du M, Zhou X, et al. High-grade papillary early gastric carci-noma with high risk for lymph node metastasis and poor prog-nosis: a clinicopathologic study of 96 cases among 1 136 consecutive radical gastrectomies. Am J Surg Pathol, 2021, 45(12): 1661-1668.
19.	Liu Y, Wang L, Du W, et al. Identification of high-risk factors associated with mortality at 1-, 3-, and 5-year intervals in gastric cancer patients undergoing radical surgery and immunotherapy: an 8-year multicenter retrospective analysis. Front Cell Infect Microbiol, 2023, 13: 1207235. doi: 10.3389/fcimb.2023.1207235.
20.	Fulop T, Larbi A, Kotb R, et al. Aging, immunity, and cancer. Discov Med, 2011, 11(61): 537-550.
21.	Hoeijmakers JH. DNA damage, aging, and cancer. N Engl J Med, 2009, 361(15): 1475-1485.
22.	Kim J, Sun CL, Mailey B, et al. Race and ethnicity correlate with survival in patients with gastric adenocarcinoma. Ann Oncol, 2010, 21(1): 152-160.
23.	Wang A, Squires MH, Melis M, et al. Stage-specific prognostic effect of race in patients with resectable gastric adenocarcinoma: an 8-institution study of the US Gastric Cancer Collaborative. J Am Coll Surg, 2016, 222(4): 633-643.
24.	王新友, 张冯祥, 郭建平, 等. 胃印戒细胞癌的预后分析: 一项倾向性评分匹配研究. 消化肿瘤杂志(电子版), 2021, 13(3): 192-198.
25.	中华人民共和国国家卫生健康委员会医政医管局. 胃癌诊疗指南(2022年版). 中华消化外科杂志, 2022, 21(9): 1137-1164.
26.	Hugen N, Verhoeven RH, Lemmens VE, et al. Colorectal signet-ring cell carcinoma: benefit from adjuvant chemotherapy but a poor prognostic factor. Int J Cancer, 2015, 136(2): 333-339.
27.	Li Y, Ma FH, Xue LY, et al. Neoadjuvant chemotherapy vs upfront surgery for gastric signet ring cell carcinoma: a retrospective, propensity score-matched study. World J Gastroenterol, 2020, 26(8): 818-827.
28.	Giampieri R, Baleani MG, Bittoni A, et al. Impact of signet-ring cell histology in the management of patients with non-metastatic gastric cancer: results from a retrospective multicenter analysis comparing FLOT perioperative chemotherapy vs. surgery followed by adjuvant chemotherapy. Cancers (Basel), 2023, 15(13): 3342.
29.	Leporini C, Ammendola M, Marech I, et al. Targeting mast cells in gastric cancer with special reference to bone metastases. World J Gastroenterol, 2015, 21(37): 10493-10501.
30.	Petrillo A, Giunta EF, Pappalardo A, et al. Bone metastases from gastric cancer: what we know and how to deal with them. J Clin Med, 2021, 10(8): 1777. doi: 10.3390/jcm10081777.
31.	郭跃楠, 张汝鹏, 王维佳, 等. 胃癌肺转移患者生存率的影响因素分析. 中华胃肠外科杂志, 2016, 19(1): 58-61.

1. Japanese Gastric Cancer Association. Japanese gastric cancer treatment guidelines 2014 (ver. 4). Gastric Cancer, 2017, 20(1): 1-19.
2. 沈亦敏, 李元元, 王舟, 等. 不同病理亚型胃印戒细胞癌的临床预后分析. 解放军医学杂志, 2023-10-27. http://kns.cnki.net/kcms/detail/11.1056.R.20230526.1736.008.html.
3. Pernot S, Voron T, Perkins G, et al. Signet-ring cell carcinoma of the stomach: impact on prognosis and specific therapeutic challenge. World J Gastroenterol, 2015, 21(40): 11428-11438.
4. Taghavi S, Jayarajan SN, Davey A, et al. Prognostic significance of signet ring gastric cancer. J Clin Oncol, 2012, 30(28): 3493-3498.
5. Bamboat ZM, Tang LH, Vinuela E, et al. Stage-stratified prognosis of signet ring cell histology in patients undergoing curative resection for gastric adenocarcinoma. Ann Surg Oncol, 2014, 21(5): 1678-1685.
6. 张莉芊, 陈闽霞, 杨沛轩, 等. 术后辅助放疗对中晚期胃印戒细胞癌患者预后的影响: 基于人群的回顾性研究. 第二军医大学学报, 2021, 42(9): 981-987.
7. 黄坤, 赵平武, 白斗, 等. 不同病理学类型的腹膜后脂肪肉瘤患者的预后分析及临床评价. 中国普通外科杂志, 2021, 30(10): 1212-1228.
8. Chen XB, Xu ZJ, Liu T, et al. Analysis of related risk factors and prognostic factors of gastric cancer with bone metastasis: a SEER-based study. J Immunol Res, 2022, 2022: 3251051. doi: 10.1155/2022/3251051.
9. Wang J, Qin D, Tao Z, et al. Identification of cuproptosis-related subtypes, construction of a prognosis model, and tumor microenvironment landscape in gastric cancer. Front Immunol, 2022, 13: 1056932. doi: 10.3389/fimmu.2022.1056932.
10. Joshi SS, Badgwell BD. Current treatment and recent progress in gastric cancer. CA Cancer J Clin, 2021, 71(3): 264-279.
11. Yu JI, Lim DH, Lee J, et al. Necessity of adjuvant concurrent chemo-radiotherapy in D2-resected LN-positive gastric cancer. Radiother Oncol, 2018, 129(2): 306-312.
12. Deb S, Austin PC, Tu JV, et al. A review of propensity-score methods and their use in cardiovascular research. Can J Cardiol, 2016, 32(2): 259-265.
13. Benedetto U, Head SJ, Angelini GD, et al. Statistical primer: propensity score matching and its alternatives. Eur J Cardiothorac Surg, 2018, 53(6): 1112-1117.
14. Liu L, Wang Q, Yuan H. Clinicopathological characteristics and prognostic factors of primary bladder signet ring cell carcinoma. J Healthc Eng, 2022, 2022: 3224616. doi: 10.1155/2022/3224616.
15. Fung BM, Patel M, Patel N, et al. Signet ring cell gastric carcinoma: clinical epidemiology and outcomes in a predominantly Latino county hospital population. Dig Dis Sci, 2021, 66(4): 1240-1248.
16. Yu JM, Zhan ZW, Zhen JX, et al. Clinical characteristics and prognostic analysis of patients with signet ring cell gastric carcinoma. Technol Cancer Res Treat, 2020, 19: 1533033820983812. doi: 10.3389/fsurg.2022.819018.
17. Biondi A, D’Ugo D, Cananzi F, et al. Prognostic indicators in stage Ⅳ surgically treated gastric cancer patients: a retrospective multi-institutional study. Dig Surg, 2019, 36(4): 331-339.
18. Cheng Y, Du M, Zhou X, et al. High-grade papillary early gastric carci-noma with high risk for lymph node metastasis and poor prog-nosis: a clinicopathologic study of 96 cases among 1 136 consecutive radical gastrectomies. Am J Surg Pathol, 2021, 45(12): 1661-1668.
19. Liu Y, Wang L, Du W, et al. Identification of high-risk factors associated with mortality at 1-, 3-, and 5-year intervals in gastric cancer patients undergoing radical surgery and immunotherapy: an 8-year multicenter retrospective analysis. Front Cell Infect Microbiol, 2023, 13: 1207235. doi: 10.3389/fcimb.2023.1207235.
20. Fulop T, Larbi A, Kotb R, et al. Aging, immunity, and cancer. Discov Med, 2011, 11(61): 537-550.
21. Hoeijmakers JH. DNA damage, aging, and cancer. N Engl J Med, 2009, 361(15): 1475-1485.
22. Kim J, Sun CL, Mailey B, et al. Race and ethnicity correlate with survival in patients with gastric adenocarcinoma. Ann Oncol, 2010, 21(1): 152-160.
23. Wang A, Squires MH, Melis M, et al. Stage-specific prognostic effect of race in patients with resectable gastric adenocarcinoma: an 8-institution study of the US Gastric Cancer Collaborative. J Am Coll Surg, 2016, 222(4): 633-643.
24. 王新友, 张冯祥, 郭建平, 等. 胃印戒细胞癌的预后分析: 一项倾向性评分匹配研究. 消化肿瘤杂志(电子版), 2021, 13(3): 192-198.
25. 中华人民共和国国家卫生健康委员会医政医管局. 胃癌诊疗指南(2022年版). 中华消化外科杂志, 2022, 21(9): 1137-1164.
26. Hugen N, Verhoeven RH, Lemmens VE, et al. Colorectal signet-ring cell carcinoma: benefit from adjuvant chemotherapy but a poor prognostic factor. Int J Cancer, 2015, 136(2): 333-339.
27. Li Y, Ma FH, Xue LY, et al. Neoadjuvant chemotherapy vs upfront surgery for gastric signet ring cell carcinoma: a retrospective, propensity score-matched study. World J Gastroenterol, 2020, 26(8): 818-827.
28. Giampieri R, Baleani MG, Bittoni A, et al. Impact of signet-ring cell histology in the management of patients with non-metastatic gastric cancer: results from a retrospective multicenter analysis comparing FLOT perioperative chemotherapy vs. surgery followed by adjuvant chemotherapy. Cancers (Basel), 2023, 15(13): 3342.
29. Leporini C, Ammendola M, Marech I, et al. Targeting mast cells in gastric cancer with special reference to bone metastases. World J Gastroenterol, 2015, 21(37): 10493-10501.
30. Petrillo A, Giunta EF, Pappalardo A, et al. Bone metastases from gastric cancer: what we know and how to deal with them. J Clin Med, 2021, 10(8): 1777. doi: 10.3390/jcm10081777.
31. 郭跃楠, 张汝鹏, 王维佳, 等. 胃癌肺转移患者生存率的影响因素分析. 中华胃肠外科杂志, 2016, 19(1): 58-61.

CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY

Effect of surgical treatment on prognosis in patients with gastric signet-ring cell carcinoma: a SEER-based study

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content